These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 22425627)

  • 1. Phosphate: a stealthier killer than previously thought?
    Gonzalez-Parra E; Tuñón J; Egido J; Ortiz A
    Cardiovasc Pathol; 2012; 21(5):372-81. PubMed ID: 22425627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk.
    Toussaint ND; Pedagogos E; Tan SJ; Badve SV; Hawley CM; Perkovic V; Elder GJ
    Nephrology (Carlton); 2012 Jul; 17(5):433-44. PubMed ID: 22574672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer?
    Negri AL
    J Nephrol; 2010; 23(6):653-7. PubMed ID: 20349415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of calcium on cardiovascular events in patients with kidney disease and in a healthy population.
    West SL; Swan VJ; Jamal SA
    Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S41-7. PubMed ID: 20089502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of phosphate binders in chronic kidney disease.
    Ketteler M; Biggar PH
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
    Mason MA; Shepler BM
    Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ten-year experience with sevelamer and calcium salts as phosphate binders.
    Raggi P; Vukicevic S; Moysés RM; Wesseling K; Spiegel DM
    Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S31-40. PubMed ID: 20089501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early initiation of phosphate lowering dietary therapy in non-dialysis chronic kidney disease: a critical review.
    Sigrist MK; Chiarelli G; Lim L; Levin A
    J Ren Care; 2009 Mar; 35 Suppl 1():71-8. PubMed ID: 19222735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Management of hyperphosphatemia in dialysis patients: the role of phosphate binders].
    Malberti F
    G Ital Nefrol; 2010; 27 Suppl 52():S47-54. PubMed ID: 21132662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality].
    Koizumi M; Fukagawa M
    Clin Calcium; 2010 Nov; 20(11):1700-8. PubMed ID: 21037391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonphosphate-binding effects of sevelamer--are they of clinical relevance?
    Marangon N; Lindholm B; Stenvinkel P
    Semin Dial; 2008; 21(5):385-9. PubMed ID: 18573137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Newly development of phosphate binders in hyperphosphatemic patients with kidney dysfunction].
    Negi S; Yamanaka S; Koreeda D; Yashiro M; Shigematsu T
    Clin Calcium; 2012 Oct; 22(10):1557-66. PubMed ID: 23023637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
    Martin KJ; González EA
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Phosphate metabolism and nutritional therapy in predialysis patients].
    Hamada Y; Usami M
    Clin Calcium; 2012 Oct; 22(10):1577-82. PubMed ID: 23023639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphate levels and cardiovascular disease in the general population.
    Foley RN
    Clin J Am Soc Nephrol; 2009 Jun; 4(6):1136-9. PubMed ID: 19423568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphate metabolism in the setting of chronic kidney disease: significance and recommendations for treatment.
    Kestenbaum B
    Semin Dial; 2007; 20(4):286-94. PubMed ID: 17635817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of sevelamer treatment on cardiovascular abnormalities in mice with chronic renal failure.
    Maizel J; Six I; Dupont S; Secq E; Dehedin B; Barreto FC; Benchitrit J; Poirot S; Slama M; Tribouilloy C; Choukroun G; Mazière JC; Drueke TB; Massy ZA
    Kidney Int; 2013 Sep; 84(3):491-500. PubMed ID: 23594676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hyperphosphatemia and cardiovascular risk in patients on dialysis].
    Basić-Jukić N; Kes P
    Acta Med Croatica; 2004; 58(3):207-13. PubMed ID: 15503684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hyperphosphatemia and cardiovascular diseases : impact of vascular calcification and endothelial dysfunction].
    Iijima K
    Clin Calcium; 2012 Oct; 22(10):1505-13. PubMed ID: 23023630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.